Evidence map›Paper›PMID 39787896›Full record

ArticleBiomaterials2025

Systemically administered platelet-inspired nanoparticles to reduce inflammation surrounding intracortical microelectrodes.

Longshun Li, Dhariyat M Menendez-Lustri, Aniya Hartzler, Anna Pogharian, Brett Zaorski, Alex Chen, Jaquelynn Palen, Baylee Traylor, Emma Quill, Christa L Pawlowski and 4 more

Abstract read
In one paragraph

Article in Biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Platelet Products and Artificial Platelets for Regenerative Medicine.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Longshun LiDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States; Advanced Platform Technology Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, United States.
Dhariyat M Menendez-LustriDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States; Advanced Platform Technology Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, United States.
Aniya HartzlerDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States.
Anna PogharianDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States.
Brett ZaorskiDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States.
Alex ChenDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States.
Jaquelynn PalenDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States.
Baylee TraylorHaima Therapeutics LLC, Cleveland, OH, United States.
Emma QuillHaima Therapeutics LLC, Cleveland, OH, United States.
Christa L PawlowskiHaima Therapeutics LLC, Cleveland, OH, United States.
Michael A BruckmanHaima Therapeutics LLC, Cleveland, OH, United States.
Anirban Sen GuptaDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States.
Jeffrey R CapadonaDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States; Advanced Platform Technology Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, United States.
Andrew J ShoffstallDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States; Advanced Platform Technology Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, United States. Electronic address: ajs215@case.edu.

Funding

Heteromutivalent Peptide-Lipid Nanoconstructs as Artificial Platelet AnaloguesR01HL121212 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SEN GUPTA, ANIRBAN · 2014 to 2024
$4.1M
NHLBI NIH HHS R01 HL121212RRD VA I01 RX003420
6 · The paper itself

Abstract

Intracortical microelectrodes (IMEs) are essential for neural signal acquisition in neuroscience and brain-machine interface (BMI) systems, aiding patients with neurological disorders, paralysis, and amputations. However, IMEs often fail to maintain robust signal quality over time, partly due to neuroinflammation caused by vascular damage during insertion. Platelet-inspired nanoparticles (PIN), which possess injury-targeting functions, mimic the adhesion and aggregation of active platelets through conjugated collagen-binding peptides (CBP), von Willebrand Factor-binding peptides (VBP), and fibrinogen-mimetic peptides (FMP). Systemically administered PINs can potentially enhance hemostasis and promote the resealing of IME insertion-induced leaky blood-brain barrier (BBB), thereby attenuating the influx of blood-derived proteins into the brain parenchyma that trigger neuroinflammation. This study explores the potential of PINs to mitigate neuroinflammation at implant sites. Male Sprague Dawley rats underwent craniotomies and IME implantations, followed by a single dose of Cy5 labeled PINs (2 mg/kg). Rats were sacrificed at intervals from 0 to 4 days post-implantation (DPI) for biodistribution analysis using an in vivo live imaging system (IVIS) and immunohistochemistry (IHC) to assess neuroinflammation, BBB permeability, and active platelet distribution. Another cohort of rats received weekly PINs, trehalose buffer (TH, diluent control), or control nanoparticles (CP, PEG-coated liposomes) for 4 weeks, with similar endpoint analyses. Results indicated that PIN concentrations were significantly elevated near IME interfaces acutely (0-4 DPI) and after 4 weeks of repeated dosing. At 3 DPI, peak intensities of active platelets (CD62P), activated microglia/macrophages (CD68), and PINs were observed. Immunoglobulin G (IgG) was upregulated during the first 24 h near implant sites but declined thereafter. At 4 weeks, the PINs group exhibited higher intensities of active platelets and PINs, and reduced CD68 and IgG levels compared to controls. PINs effectively targeted the IME-tissue interface, alongside endogenous activated platelets, resulting in reduced neuroinflammatory and BBB-leakage markers compared to the diluent-only-infused control group. Repeated dosing of PINs presents a promising approach for enhancing the quality of neural recordings in future studies.

Indexed as

Blood PlateletsElectrodes, ImplantedInflammationNanoparticlesAnimalsBlood-Brain BarrierMaleMicroelectrodesRatsRats, Sprague-DawleyBlood-brain barrierIntracortical microelectrodesLiposome nanoparticleNeuroinflammationPlatelets

Identifiers

PMID39787896
PMCPMC13224336

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.